Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this research study is to help in the development of safe, effective and reversible male contraception. We are examining the impact of the drug Miglustat on sperm production in normal men.

We want to see if Miglustat will inhibit sperm production in men and act as a reversible male contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of sperm production. We believe Miglustat may have some potential as a safe, reversible male contraceptive.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Washington
• Collaborator: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Treatments: Miglustat

Criteria

Inclusion Criteria:

• Healthy male, normal lab test

Exclusion Criteria:

• Abnormal lab test, history or evidence of significant chronic or acute medical illness, previous or current ethanol or anabolic steroid abuse.